HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,432,271 | +4.4% | 37,494 | -1.4% | 0.01% | +9.1% |
| Q2 2023 | $1,371,922 | -8.3% | 38,035 | -2.9% | 0.01% | -15.4% |
| Q1 2023 | $1,496,208 | -32.4% | 39,178 | +0.8% | 0.01% | -38.1% |
| Q4 2022 | $2,212,158 | +49.3% | 38,878 | +3.7% | 0.02% | +40.0% |
| Q3 2022 | $1,482,000 | -9.7% | 37,488 | +0.5% | 0.02% | -6.2% |
| Q2 2022 | $1,642,000 | +13.9% | 37,318 | +3.2% | 0.02% | +33.3% |
| Q1 2022 | $1,442,000 | -1.4% | 36,154 | -0.7% | 0.01% | +9.1% |
| Q4 2021 | $1,463,000 | -2.4% | 36,394 | -1.2% | 0.01% | -8.3% |
| Q3 2021 | $1,499,000 | -5.5% | 36,846 | +5.5% | 0.01% | -7.7% |
| Q2 2021 | $1,586,000 | +1.7% | 34,933 | -6.6% | 0.01% | -7.1% |
| Q1 2021 | $1,559,000 | -3.3% | 37,384 | -1.0% | 0.01% | -6.7% |
| Q4 2020 | $1,612,000 | +57.6% | 37,751 | -3.0% | 0.02% | +50.0% |
| Q3 2020 | $1,023,000 | +28.7% | 38,930 | +31.3% | 0.01% | -9.1% |
| Q2 2020 | $795,000 | +42.7% | 29,639 | -4.3% | 0.01% | +10.0% |
| Q1 2020 | $557,000 | – | 30,962 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRAN CAPITAL MANAGEMENT, L.P. | 1,084,118 | $61,686,285 | 7.80% |
| SNYDER CAPITAL MANAGEMENT L P | 3,983,814 | $226,679,017 | 5.12% |
| First Light Asset Management, LLC | 923,119 | $52,525,471 | 4.88% |
| Redwood Investments, LLC | 441,809 | $25,138,932 | 3.37% |
| BERNZOTT CAPITAL ADVISORS | 444,728 | $25,305,023 | 3.27% |
| DOHENY ASSET MANAGEMENT /CA | 46,050 | $2,620 | 3.04% |
| Crawford Lake Capital Management, LLC | 42,171 | $2,399,530 | 2.75% |
| 2Xideas AG | 416,586 | $23,703,743 | 2.51% |
| Granite Investment Partners, LLC | 902,882 | $51,373,986 | 2.14% |
| HighMark Wealth Management LLC | 41,790 | $2,377,851 | 1.79% |